摘要
目的观察中医辨证分型联合化疗在中晚期非小细胞肺癌治疗中的疗效。方法选取2015年3月—2017年12月42例非小细胞肺癌患者为研究对象,根据随机抽签原则将受试者分为对照组和研究组,每组21例。对照组患者给予传统的化疗一线治疗,研究组患者在对照组治疗基础上联合中医辨证分型治疗。对比2组患者的近期疗效及不良反应发生率。结果研究组患者ORR为80. 95%,对照组患者ORR为52. 38%,2组比较存在统计学差异(P <0. 05)。研究组患者各不良反应的发生率均显著低于对照组,2组比较存在统计学差异(P <0. 05)。结论中医辨证分型联合化疗可有效提高近期疗效,且不良反应较低,在中晚期非小细胞肺癌治疗中具有重要应用意义。
Objective To observe the clinical efficacy of TCM syndrome differentiation combined with chemotherapy in the treatment of advanced non-small cell lung cancer. Methods From March 2015 to December 2017,42 cases of non-small cell lung cancer patients in our hospital were selected as the research objects. According to the random lottery principle,the subjects were divided into the control group and the study group,with 21 cases in each group. Patients in the control group were treated with traditional chemotherapy,and the patients in the study group were treated with TCM syndrome differentiation on the basis of the control group. The short-term efficacy and incidence of adverse reactions were compared between the two groups. Results The ORR of the study group and the control group was 80. 95% and 52.38%,and there were statistical differences between the two groups( P < 0. 05). The incidence of adverse reactions in the study group was significantly lower than that in the control group,and there was statistical difference between the two groups( P < 0. 05). Conclusion TCM syndrome differentiation combined with chemotherapy can effectively improve short-term curative effect,and has lower side effects,which is of great significance in the treatment of advanced non-small cell lung cancer.
作者
加依娜.铁木尔汗
梁振玺
Gajna Timur Khan;LIANG Zhenxi(Department of Traditional Chinese Medicine,The Ninth Division Hospital of Xinjiang Corps,Xinjiang Tacheng 834601,China)
出处
《光明中医》
2018年第21期3232-3233,共2页
GUANGMING JOURNAL OF CHINESE MEDICINE
关键词
中西医结合疗法
化疗
中晚期
非小细胞肺癌
Therapy of integrated medicine
Chemotherapy
Advanced
Non-small cell lung cancer
